highly potent and selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia. The achievement of this milestone ...

The management team at Alkermes highlighted their concentrated efforts on advancing a comprehensive development program for their oral orexin 2 receptor (OX2R) agonist product candidates.

The management team at Alkermes highlighted their concentrated efforts on advancing a comprehensive development program for their oral orexin 2 receptor (OX2R) agonist product candidates. The lead ...

Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes that Centessa Pharmaceuticals has initiated a Phase 2 trial of ORX750, an investigational, orally ...

highly potent and selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia. The achievement of this milestone ...

Ltd. ("Nxera” or "the Company”; TSE 4565) - formerly known as Sosei Group or Sosei Heptares - notes that Centessa Pharmaceuticals has initiated a Phase 2 trial of ORX750, an investigational, orally ...